Mankind may finally have a weapon to fight two of the world's deadliest diseases. A University of Central Florida biomedical researcher has developed what promises to be the first low-cost dual vaccine against malaria and cholera.
There is no FDA-approved vaccine to prevent malaria, a mosquito-borne illness that kills more than 1 million people annually. Only one vaccine exists to fight cholera, a diarrheal illness that is common in developing countries and can be fatal. The lone vaccine is too expensive to prevent outbreaks in developing countries after floods, and children lose immunity within three years of getting the current vaccine.
"I'm very encouraged because our technique works well and provides an affordable way to get vaccines to people who need them most and can least afford them," said lead scientist Henry Daniell.
Daniell's team genetically engineered tobacco and lettuce plants to produce the vaccine. Researchers gave mice freeze-dried plant cells (orally or by injection) containing the vaccine. They then challenged the mice with either the cholera toxin or malarial parasite. The malaria parasite studies were completed in fellow UCF professor Debopam Chakrabarti's lab.
Untreated rodents contracted diseases quickly, but the mice who received the plant-grown vaccines showed long-lasting immunity for more than 300 days (equivalent to 50 human years).
Results from the National Institutes of Health-funded research are published in this month's Plant Biotechnology.
Clinical trials are needed, and Daniell is hopeful that the results with mice will translate to humans. It could be yet another example of plants delivering life-saving medicines.
The dual vaccine follows a string of other "green" vaccines developed in Daniell's lab. He's created vaccines against anthrax and black plague that generated a congratulatory call from the top U.S. homeland security official and was featured on the Discovery Channel. He's also successfully grown insulin in plants to find what could be a long-lasting cure for diabetes. Daniell's team continues to research these vaccines and is looking for investors to help fund clinical trials.
Producing vaccines in plants is less expensive than traditional methods because it requires less labor and technology, Daniell said.
"We're talking about producing mass quantities for pennies on the dollar," he said. "And distribution to mass populations would be easy because it could be made into a simple pill, like a vitamin, which many people routinely take now. There is no need for expensive purification, cold storage, transportation or sterile delivery via injections."
For Daniell, his research is more than his day job. His passion to find vaccines for the world's top 10 diseases as defined by the World Health Organization comes from growing up in India. He watched many of his childhood friends contract malaria, cholera and other diseases.
Daniell joined UCF's Burnett School of Biomedical Sciences in the College of Medicine in 1998. His research led to the formation of the university's first biotechnology company. Daniell also became only the 14th American in the last 222 years to be elected the Italian National Academy of Sciences. In 2007 he was named a Fellow of the American Association for the Advancement of Sciences.
"I'm not done yet," he said. "I still have more diseases to attack."
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.